Bispecific antibody · Immune activation, directed at CD3 (CD3E) and B-cell maturation antigen (BCMA) (TNFRSF17) · developed by Janssen Biotech
Teclistamab is a bispecific T-cell engaging antibody that binds CD3 on T-cells and B-cell maturation antigen (BCMA) on multiple myeloma cells and some healthy B-lineage cells. By cross-linking T-cells with tumor cells, it activates T-cells, triggers proinflammatory cytokine release and lyses myeloma cells. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 10, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07030517 | Phase 4 | Multiple Myeloma | Active not recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →